OSENI (Alogliptin and Pioglitazone)

OSENI is a combination medication that contains two active ingredients, alogliptin and pioglitazone. It is primarily used to manage blood sugar levels in individuals with type 2 diabetes. OSENI combines two different classes of medications to address the management of type 2 diabetes. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while pioglitazone is a thiazolidinedione. Alogliptin helps regulate blood sugar, while pioglitazone improves insulin sensitivity and reduces glucose production by the liver.

Indications and Uses

OSENI is indicated for the following purposes:

• Treatment of type 2 diabetes mellitus in adults.

• It is used to improve glycemic control in individuals who require treatment with both alogliptin and pioglitazone.

Dosage and Administration

The dosage of OSENI is determined by a healthcare provider based on the patient's specific condition and their response to the medication. The tablets are taken orally, typically once daily with or without food. The dose may be adjusted over time to achieve optimal blood sugar control.

Contraindications

OSENI should not be used in individuals with known hypersensitivity to alogliptin, pioglitazone, or any of its components. It is essential to discuss any allergies or potential reactions with a healthcare provider.

Adverse Effects and Side Effects

Common side effects of OSENI may include:

• Upper respiratory tract infection.

• Headache.

• Back pain.

• Nasopharyngitis (inflammation of the throat and nasal passages).

• Edema (fluid retention).

Serious side effects are possible and may include:

• Heart failure or worsening of heart failure.

• Liver problems.

• Low blood sugar (hypoglycemia) when used in combination with other antidiabetic medications.

It is crucial to report any severe or unusual side effects to your healthcare provider.

Storage and Shelf Life

Store OSENI at room temperature (20-25°C or 68-77°F), away from excessive heat and moisture. Protect it from light. Do not use OSENI after the expiration date.

Packaging and Presentation

OSENI is available in tablet form, with various strengths of alogliptin and pioglitazone.

Regulatory Information

OSENI is subject to regulation by health authorities to ensure its safety and efficacy. It is essential to use this medication as directed by a healthcare professional and in accordance with local regulations.

References

Always consult with your healthcare provider and refer to the official prescribing information and product labeling for the most up-to-date and comprehensive information on OSENI. Your healthcare provider will guide you in the proper use of this medication, monitor your progress, and tailor the treatment to your specific medical condition.